Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 527

1.

Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients.

Wainstein J, Metzger M, Boaz M, Minuchin O, Cohen Y, Yaffe A, Yerushalmy Y, Raz I, Harman-Boehm I.

Diabet Med. 2005 Aug;22(8):1037-46.

PMID:
16026370
2.

Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.

Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW; Insulin Aspart CSII/MDI Comparison Study Group.

Diabetes Care. 2005 Mar;28(3):533-8.

PMID:
15735183
4.

Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study.

Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR.

Diabetes Care. 2003 Sep;26(9):2598-603.

PMID:
12941725
5.

Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial.

Hoogma RP, Hammond PJ, Gomis R, Kerr D, Bruttomesso D, Bouter KP, Wiefels KJ, de la Calle H, Schweitzer DH, Pfohl M, Torlone E, Krinelke LG, Bolli GB; 5-Nations Study Group.

Diabet Med. 2006 Feb;23(2):141-7.

PMID:
16433711
7.

Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.

Torres I, Ortego J, Valencia I, García-Palacios MV, Aguilar-Diosdado M.

Exp Clin Endocrinol Diabetes. 2009 Sep;117(8):378-85. doi: 10.1055/s-0029-1225337. Epub 2009 Jul 23.

PMID:
19629931
8.

A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.

Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV.

Diabetes Care. 2004 Jul;27(7):1554-8.

PMID:
15220227
11.
12.

In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.

Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A.

Diabet Med. 2008 Mar;25(3):326-32. doi: 10.1111/j.1464-5491.2007.02365.x.

PMID:
18307459
13.

The impact of continuous subcutaneous insulin infusion and multiple daily injections of insulin on glucose variability in older adults with type 2 diabetes.

Johnson SL, McEwen LN, Newton CA, Martin CL, Raskin P, Halter JB, Herman WH.

J Diabetes Complications. 2011 Jul-Aug;25(4):211-5. doi: 10.1016/j.jdiacomp.2010.09.005. Epub 2010 Nov 9.

PMID:
21062674
15.

Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years.

Jakisch BI, Wagner VM, Heidtmann B, Lepler R, Holterhus PM, Kapellen TM, Vogel C, Rosenbauer J, Holl RW; German/Austrian DPV Initiative and Working Group for Paediatric Pump Therapy.

Diabet Med. 2008 Jan;25(1):80-5. doi: 10.1111/j.1464-5491.2007.02311.x.

PMID:
18199134
16.
17.

Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial.

Weintrob N, Benzaquen H, Galatzer A, Shalitin S, Lazar L, Fayman G, Lilos P, Dickerman Z, Phillip M.

Pediatrics. 2003 Sep;112(3 Pt 1):559-64.

PMID:
12949284
18.
19.
20.

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.

Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.

Ann Intern Med. 2008 Oct 21;149(8):531-9.

PMID:
18936501

Supplemental Content

Support Center